Market analysis of U.S. sperm banks reveals significant price increases
A historical and contemporary look at donor sperm pricing in the United States. (Hobbs, 2026)
Hobbs, C. L., & Martin, C. E. (2026). A historical and contemporary look at donor sperm pricing in the United States. Fertility and Sterility. https://doi.org/10.1016/j.fertnstert.2026.04.022
Geographic Region: United States.
Research Question: How have donor sperm prices changed over the past decade in the United States, and what is the current pricing landscape across U.S. sperm banks stratified by vial type and donor identity status?
Design: Cross-sectional market analysis with longitudinal price trend data. The authors collected donor sperm pricing information from the publicly listed websites of five of the largest U.S. sperm banks in April 2025. They obtained prices for vials prepared for four insemination methods: intrauterine insemination (IUI), intracervical insemination (ICI), in vitro fertilization (IVF), and intracytoplasmic sperm injection (ICSI). Prices were stratified by donor identity status to assess financial implications of the industry shift toward identity-disclosure donors (who agree to share identifying information with offspring at age 18) versus non-identified donors (who remain anonymous to recipients and offspring). Two sperm banks provided longitudinal pricing data spanning 9–10 years. Historical prices were inflation-adjusted to 2025 U.S. dollars using the Consumer Price Index and standard inflation adjustment formulas.
Sample: Five large U.S. sperm banks. Non-identified donor options were available at only 2 of the 5 banks sampled in 2025; the other 3 had already discontinued non-identified donations. Longitudinal pricing data spanning 9–10 years came from only two of these banks. The summary cannot assess whether these five banks represent the market, are skewed toward particular regions or pricing strategies, or whether their pricing patterns generalize beyond them.
Editor’s Note: This research is observational and conducted on publicly available data. It documents market behavior but cannot establish causation or isolate the independent effects of changes in norms around factors such as donor disclosure status, actual cost increases for banks, regulatory burden, or market concentration/limited competition.
Key Findings
Price differences across vial types reflect differences in total motile sperm counts and preparation techniques.
2025 average pricing: In April 2025, across five major U.S. sperm banks, IUI and ICI vials averaged $1,968 for identity-disclosure donors and $1,495 for non-identified donors. IVF vial average costs were $1,789 for identity-disclosure donors and $1,245 for non-identified donors. ICSI vials were the least expensive, averaging $1,841 for identity-disclosure donors and $1,195 for non-identified donors.
Inflation-adjusted price trends (2016–2025): One sperm bank reported non-identified donor pricing from 2016–2024, showing inflation-adjusted increases of 23% (IUI) and 78% (IVF). Two sperm banks reported identity-disclosure pricing from 2016–2025, showing increases of 58% (IUI) and 99% (IVF).
Absolute dollar increases (2016–2025, inflation-adjusted): At one bank, inflation-adjusted prices increased by $216 for non-identified IUI vials and $449 for non-identified IVF vials. For identity-disclosure donors, mean prices across two banks increased by $574 for IUI vials and $717 for IVF vials over the 10-year period.
Limitations: The authors do not report selection criteria for the ‘five largest’ banks or their geographic distribution, market position, or patient demographics. Only 2 of 5 banks offered non-identified donors in 2025. Longitudinal data come from only 2 banks with different donor type coverage. The research cannot assess whether these banks represent the market broadly or are skewed toward particular regions, pricing strategies, or patient populations. No analysis of the relationship between Colorado Senate Bill 22-224 (which mandated identity disclosure for all gamete donors used by patients in Colorado and went into effect in 2025) and the timing or magnitude of price increases.
Applications: This research documents commercial sperm bank pricing, but is not designed to explain why prices increased, whether disclosure mandates drove the shift, or who is excluded from commercial banking. More work is needed to understand the effects of regulations on access to third-party reproduction. Building legal infrastructure for known-donor arrangements could expand choices by clarifying parentage status and protecting known donors and recipients.
Funding Source: No funding was reported for this project.
Lead Author: Cassie Hobbs is a reproductive endocrinologist at the Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania. The author did not disclose a personal connection to donor conception.
Regulatory Context
The U.S. lacks comprehensive federal regulation of gamete donation and donor conception. The fertility industry is largely self-regulated.
The Food and Drug Administration oversees infectious disease screening and testing of donors but does not regulate pricing or donor identity practices.
The American Society for Reproductive Medicine provides ethical guidelines and recommendations on donation practices, but these are not legally binding.
There are no federal legal limits on donor compensation. A 2011 court ruling (Kamakahi v. ASRM) determined that price caps violate antitrust laws.
The U.S. does not have federal laws prohibiting anonymous donation; practice varies by bank and state.
In 2022, Colorado became the first state to mandate identity disclosure for all gamete donors (Senate Bill 22-224).
Some states have enacted laws regarding assisted reproduction and parentage, but these vary widely; there is no national donor registry and no uniform access-to-information law for donor-conceived people.
Related Posts